Clinical Trial Update: Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an RNA-lipid particle vaccine intended to sensitize tumors to anti-PD-1 therapy in patients with melanoma and soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Soft Tissue Sarcoma

Drugs mentioned

• RNA-lipid Particle Vaccine (RNA-LP)

Snippet

Sponsor: University of Florida | Conditions: Melanoma, Soft Tissue Sarcoma | Phase 1 | Status: RECRUITING